Disappointing trial results for Otonomy
May 22, 2015 at 11:41 AM EDT
Otonomy
Inc. (Nasdaq: OTIC) reported disappointing results from a Phase 2b trial of
its unilateral Meniere's disease treatment OTO-104 sending the stock price plummeted $7.04 to $24.01.
